Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

人类和非人类伯氏疏螺旋体诊断生物标志物的鉴定

基本信息

批准号：
8892078
负责人：
David P AuCoin
金额：
$ 29.27万
依托单位：
DXDISCOVERY, INC.
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-15 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8892078
关键词：
Animals Antibody Response Antigens Area Benchmarking Biological Assay Biological Markers Blood Borrelia burgdorferi Businesses Case Study Centers for Disease Control and Prevention (U.S.)Communicable Diseases Data Detection Development Diagnosis Diagnostic Diagnostic tests Disease Early Diagnosis Enzyme-Linked Immunosorbent Assay Foundations Goals Health Human Immunoassay Infection Laboratories Lateral Lead Lipoproteins Lyme Disease Macaca Membrane Methods Modeling Monoclonal Antibodies National Institute of Allergy and Infectious Disease Nevada Order Spirochaetales Patients Phase Primates Proteins Public Health Research Sampling Sensitivity and Specificity Serologic tests Serum Small Business Technology Transfer Research Solutions Staging Techniques Technology Universities Validation Work base diagnostic assay experience in vivo innovation microbial microorganism antigen nonhuman primate novel novel diagnostics pathogen point-of-care diagnostics pre-clinical prototype

项目摘要

DESCRIPTION (provided by applicant): The number of Lyme disease cases in the US has been recently estimated by the CDC at 300,000 cases/year. This is major public health concern. Currently available diagnostics rely on detection of the antibody response (serology) to Borrelia burgdorferi, the causative agent of Lyme disease. However, serological tests are not accurate during the early stages of Lyme disease. Direct detection of B. burgdorferi antigens within patient samples may be the only solution to an accurate early diagnosis. This application focuses on validating the presence B. burgdorferi VlsE protein in patient samples. VlsE was recently determined to accumulate in a nonhuman primate model of Lyme disease. In addition, the project seeks to identify new diagnostic biomarkers for Lyme disease by utilizing a novel biomarker discovery platform termed, In vivo Microbial Antigen Discovery or InMAD. The overall goal is to identify multiple early Lyme disease biomarkers that can be targeted by a rapid and sensitive immunoassay.

描述（由申请人提供）：美国疾病预防控制中心（CDC）最近以300,000病例估算了美国莱姆病病例的数量。这是主要的公共卫生问题。当前可用的诊断依赖于对莱姆病的病因伯格多菲利（Borrelia burgdorferi）抗体反应（血清学）的检测。但是，在莱姆病的早期阶段，血清学检查并不准确。直接检测患者样品中的伯氏芽孢杆菌抗原可能是准确早期诊断的唯一解决方案。该应用重点是验证患者样品中的B. burgdorferi vlse蛋白。最近确定VLSE积累在莱姆病的非人类灵长类动物模型中。此外，该项目旨在通过利用一种称为体内微生物抗原发现或INMAD的新型生物标志物发现平台来鉴定莱姆病的新诊断生物标志物。总体目标是确定可以通过快速和敏感的免疫测定标准来瞄准的多个早期莱姆病生物标志物。